A Study of NAC for AUD (NAC)
Alcohol Use Disorder
About this trial
This is an interventional treatment trial for Alcohol Use Disorder
Eligibility Criteria
Inclusion criteria:
- Greater than or equal to 18 years of age
- Meets DSM-V criteria for alcohol use disorder on the SCID-5
- MHS Healthcare Beneficiary
NOTE. While we are recruiting explicitly from the Addiction Treatment Services (ATS) patient population, we do not require that they are currently receiving treatment at ATS. For participants that are not currently in care we will provide them with resources to pursue psychotherapy while engaged in our study as outlined in the interview treatment questions and physical and mental health resource document.
Exclusion criteria:
- Lifetime clinical diagnosis of schizophrenia or bipolar disorder
- Currently receiving medication for the treatment of alcohol use disorder including oral or injectable naltrexone (ReVia, Vivitrol), disulfiram (Antabuse), and acamprosate (Campral).
- Pregnancy
- Lack of English fluency sufficient to complete study measures.
- Trying to get pregnant in the next 4 months.
- Hospitalized because of alcohol use in the past 12 months.
- History of seizures or delirium tremens.
- History of liver disease
- Diagnosis of a neurocognitive disorder (e.g., dementia, alzheimer's, mental retardation).
- Individuals who were never enrolled into Addiction Treatment Services
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
N-acetylcysteine
Placebo
25 participants randomly selected to receive 1500 milligrams of oral n-acetylcysteine twice daily for 7 weeks.
25 participants randomly selected to receive placebo twice daily for 7 weeks.